Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

NEA Management Company 13F Holdings (Q2 2026)

According to its SEC 13F filed on Aug 14, 2026, NEA Management Company reported 26 long positions worth $1.59B as of Jun 30, 2026. TRVI is 15.5% of the portfolio and the top 10 holdings are 90%. Against Q1 2026 it opened 1 new positions, added to 0, trimmed 2 and exited 1. 3 holdings have a dated FDA decision or data readout in the next 90 days, and 12 more expect one in a stated window such as "H2 2026".

Data as of Jun 30, 2026SEC 13F filed Aug 14, 2026Next filing (Q3 2026) due Nov 16, 2026Value as filed; options at underlying sharesLong positions only
Market Value$ 1.59 B13F value, as filed
QoQ Changes-9.73 %13F value vs the previous quarter
Holdings26 26 stocks · 0 option positions
PeriodQ2 202613F reporting quarter
Holdings in Top 20 % top 10: 90% of the portfolio
Activity vs Q1 20261 new0 added · 2 trimmed · 1 exits
Catalysts ahead3dated in 90 days · +12 in a stated window

Catalysts ahead in this portfolio

Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval

Nov 8, 2026CRSPPhase 1 data presentation: zugocabtagene geleucel (zugo-cel)PoA 18%
Nov 8, 2026NKTXPhase 1/2 data presentation: NKX019PoA 18%

1 more with a subscription

What changed vs Q1 2026

KPTIKaryopharm$6M

Full lists with a subscription

Portfolio over time

13F value by quarter, Q1 2021 to Q2 2026

Q1 2021: $4.46BQ2 2026: $1.59B

By company stage (share of value)

Clinical 72%Commercial 22%Other 6%

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 26. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
MBX
MBX
MBX Biosciences, Inc.
3.61 M
199.52 M
12.6
Unchanged
Clinical
Expected 2026
Phase 2a data readout
ORIC
ORIC
ORIC Pharmaceuticals, Inc.
4.12 M
44.60 M
2.8
Unchanged
Clinical
None in 90 days
ZBIO
ZBIO
Zenas BioPharma, Inc.
4.02 M
102.11 M
6.4
Unchanged
Clinical
Expected 2026
IND Submission
KRRO
KRRO
Korro Bio, Inc.
1.30 M
17.11 M
1.1
Unchanged
Clinical
None in 90 days
TRVI
TRVI
Trevi Therapeutics, Inc.
13.22 M
246.59 M
15.5
Unchanged
Clinical
Expected Q4 2026
Phase 2b data readout
OKUR
OKUR
OnKure Therapeutics, Inc.
478.55 K
2.18 M
0.1
Unchanged
Clinical
Expected H2 2026
Phase 1a/1b data readout

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about NEA Management Company's 13F

What does NEA Management Company own?

26 stocks worth $1.59B at Jun 30, 2026, as reported in its 13F, led by TRVI (15.5% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q1 2026: 1 new positions, 0 increases, 2 reductions and 1 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by NEA Management Company, LLC, accession 0001072613-26-000684, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.